<DOC>
	<DOCNO>NCT01179828</DOCNO>
	<brief_summary>Drug therapy patient chronic low back pain major challenge physician . One problem lack knowledge prediction drug efficacy choose patient . Usually one class pain medication give patient similar clinical picture , although different pain mechanism may responsible clinical picture . Another reason variable drug efficacy genetic polymorphism , may reason unique drug produce different response ( lack analgesic effect excessive effect side-effects . Quantitative sensory test method document alteration pain perception system . Linking genetic polymorphism quantitative sensory testing may give u tool anticipation drug efficacy .</brief_summary>
	<brief_title>Linking Altered Central Pain Processing Genetic Polymorphism Drug Efficacy Chronic Low Back Pain ( Predictio )</brief_title>
	<detailed_description>Background Drug therapy essential part pain treatment . However , minor part pain patient benefit available treatment able tolerate drug . One important limitation drug therapy lack instrument predict effect . Indeed , clinical practice `` class '' drug ( e.g . antidepressant ) give `` class '' patient ( e.g . neuropathic pain patient ) . However , within class patient different pain mechanism likely underlie pain condition different patient . If drug affect part mechanism , work patient . Another reason variability drug response genetic variation lead spectrum different response analgesic , lack efficacy exaggerated response , intolerable adverse effect . Quantitative sensory test comprises method document alteration reorganization nociceptive system . Measuring abnormal result chronic pain patient may provide u information underlie pain pathway somehow must alter . An essential question whether information link drug efficacy mechanism-based treatment approach . A important question whether assess genetic polymorphism explain different drug effect hence help select appropriate therapeutic strategy individual patient . Objective We test hypothesis correlation disturbance specific pain mechanism assess quantitative sensory test analgesic efficacy single-dose drug administration patient chronic low back pain . Genetic factor affect drug metabolism pain sensitivity analyze additional explanatory variable drug efficacy . Methods Quantitative sensory testing : Heat pain threshold tolerance , Ice water test central modulation nociceptive input ( DNIC ) , electrical pain detection temporal summation ( skin probe ) , pressure algometry pain detection threshold Drugs investigate : Imipramine , Oxycodone , Clobazam Blood sample : pharmacogenetics : Cytochrome variant CYP2D6 , CYP2C19 , CYP3A4 , COMT haplotypes , CGH-1 variant , A118G mu opioid receptor gene variant pharmacokinetics : kinetics imipramine desipramine</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<mesh_term>Imipramine</mesh_term>
	<mesh_term>Clobazam</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Low back pain NRS &gt; 2 Chronic low back pain since 6 month Exclusion Criteria pregnancy use pain medication paracetamol ibuprofen last 7 day suspicion radicular pain suspicion intervertebral disk herniation foraminal intervertebral stenosis suspicion polyneuropathy diabetes parkinson disease alzheimer disease glaucoma prostata hyperplasia void problem know heart rhythm problem heart insufficiency NYHA 34 Systemic inflammatory disease Ongoing oncologic disease drug alcohol abuse Significant depressive disease ( BDIFS &gt; 9 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Quantitative sensory test</keyword>
	<keyword>Drug efficacy</keyword>
	<keyword>Low back pain syndrome</keyword>
	<keyword>Imipramine</keyword>
	<keyword>Oxycodone</keyword>
	<keyword>Clobazam</keyword>
	<keyword>Tolterodine</keyword>
</DOC>